Company intelligence / Profile preview

Pädia

San Diego, CA, US

Ownership: Private
Employees: ~700
Development stage: Other

Overview

Nuplazid (pimavanserin): FDA approved for hallucinations/delusions in Parkinson's disease psychosis; Daybue (trofinetide): FDA approved for Rett syndrome

Therapeutic areas: NeurologyRare DiseasesPsychiatry
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Biovail (historic for Nuplazid)Genzyme (compound library licensing)

Beyond the preview

Go deeper on Pädia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pädia.

Explore the full profile